Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Second Flu Vaccine Would Boost Capacity To 30 Mil. Doses

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK submits a BLA for FluLaval, acquired as part of its 2005 purchase of ID Biomedical, to FDA March 23.
Advertisement

Related Content

GSK’s FluLaval Approval Raises Estimated Influenza Vaccine Doses To 115 Mil.
GSK’s FluLaval Approval Raises Estimated Influenza Vaccine Doses To 115 Mil.
GSK To File H5N1 Pandemic Flu Vaccine In Europe By Year-End
GSK To File H5N1 Pandemic Flu Vaccine In Europe By Year-End
Sanofi Pasteur Vaccine Manufacturing Violations Cited In FDA Warning Letter
Sanofi Pasteur Vaccine Manufacturing Violations Cited In FDA Warning Letter
GSK Vaccine Manufacturing Plan Alternates Pandemic And Seasonal Flu
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
GSK's Fluarix Gets FDA Nod Under Accelerated Approval Process

Topics

Advertisement
UsernamePublicRestriction

Register

PS063898

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel